Marktanalyse - Dry (Atrophic) Macular Degeneration – Pipeline Review, H1 2012

Dry (Atrophic) Macular Degeneration — Pipeline Review, H1 2012


Summary


Global Markets Direct’s, 'Dry (Atrophic) Macular Degeneration - Pipeline Review, H1 2012', provides an overview of the Dry (Atrophic) Macular Degeneration therapeutic pipeline. This report provides information on the therapeutic development for Dry (Atrophic) Macular Degeneration, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Dry (Atrophic) Macular Degeneration. 'Dry (Atrophic) Macular Degeneration - Pipeline Review, H1 2012' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.


Scope

- A snapshot of the global therapeutic scenario for Dry (Atrophic) Macular Degeneration.
- A review of the Dry (Atrophic) Macular Degeneration products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Dry (Atrophic) Macular Degeneration pipeline on the basis of route of administration and molecule type.
- Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.


Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Dry (Atrophic) Macular Degeneration.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players with the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Dry (Atrophic) Macular Degeneration pipeline depth and focus of Dry (Atrophic) Macular Degeneration therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Table of Contents

Table of Contents 2

List of Tables 5

List of Figures 5

Introduction 6

Global Markets Direct Report Coverage 6

Dry (Atrophic) Macular Degeneration Overview 7

Therapeutics Development 8

An Overview of Pipeline Products for Dry (Atrophic) Macular Degeneration 8

Dry (Atrophic) Macular Degeneration Therapeutics under Development by Companies 10

Late Stage Products 12

Comparative Analysis 12

Mid Clinical Stage Products 13

Comparative Analysis 13

Early Clinical Stage Products 14

Comparative Analysis 14

Pre-Clinical Stage Products 15

Comparative Analysis 15

Dry (Atrophic) Macular Degeneration Therapeutics — Products under Development by Companies 16

Companies Involved in Dry (Atrophic) Macular Degeneration Therapeutics Development 17

Alcon, Inc. 17

Genentech, Inc. 18

Pfizer Inc. 19

Ophthotech Corp. 20

Sirion Therapeutics, Inc. 21

Sucampo Pharmaceuticals, Inc. 22

Acucela Inc. 23

Aciont Inc. 24

Neurotech Pharmaceuticals, Inc. 25

Inotek Pharmaceuticals Corporation 26

Alimera Sciences, Inc. 27

MacuCLEAR, Inc. 28

Dry (Atrophic) Macular Degeneration — Therapeutics Assessment 29

Assessment by Monotherapy Products 29

Assessment by Route of Administration 30

Assessment by Molecule Type 32

Drug Profiles 34

RG7417 - Drug Profile 34

Product Description 34

Mechanism of Action 34

R&D Progress 34

ACU-4429 - Drug Profile 35

Product Description 35

Mechanism of Action 35

R&D Progress 35

NADPH Oxidase Inhibitor - Drug Profile 37

Product Description 37

Mechanism of Action 37

R&D Progress 37

Rescula - Drug Profile 38

Product Description 38

Mechanism of Action 38

R&D Progress 38

ARC1905 - Drug Profile 39

Product Description 39

Mechanism of Action 39

R&D Progress 39

SOD Mimetic - Drug Profile 40

Product Description 40

Mechanism of Action 40

R&D Progress 40

SIR-1076 - Drug Profile 41

Product Description 41

Mechanism of Action 41

R&D Progress 41

SIR-1047 - Drug Profile 42

Product Description 42

Mechanism of Action 42

R&D Progress 42

NT-501 - Drug Profile 43

Product Description 43

Mechanism of Action 43

R&D Progress 43

MC-1101 - Drug Profile 45

Product Description 45

Mechanism of Action 45

R&D Progress 45

RN6G - Drug Profile 46

Product Description 46

Mechanism of Action 46

R&D Progress 46

Iluvien - Drug Profile 47

Product Description 47

Mechanism of Action 47

R&D Progress 47

AL-8309B - Drug Profile 49

Product Description 49

Mechanism of Action 49

R&D Progress 49

SIR-1046 - Drug Profile 50

Product Description 50

Mechanism of Action 50

R&D Progress 50

OpRegen - Drug Profile 51

Product Description 51

Mechanism of Action 51

R&D Progress 51

ALK-001 - Drug Profile 52

Product Description 52

Mechanism of Action 52

R&D Progress 52

Dry (Atrophic) Macular Degeneration Therapeutics — Drug Profile Updates 54

Dry (Atrophic) Macular Degeneration Therapeutics - Dormant Products 61

Dry (Atrophic) Macular Degeneration — Product Development Milestones 62

Featured News & Press Releases 62

Jun 21, 2012: StemCells Initiates Phase I/II Clinical Trial In Dry Age-Related Macular Degeneration 62

May 07, 2012: Acucela Presents New Data From Phase IIa Trial Of ACU-4429 In Patients With Dry AMD 62

May 02, 2012: Advanced Cell Technology Announces IRB Approval For Phase I/II Trial At Massachusetts Eye and Ear For Dry Age-Related Macular Degeneration 63

Apr 24, 2012: Acucela To Present Clinical Data From Phase IIa Trial Of ACU-4429 At ARVO 2012 Annual Meeting 64

Apr 24, 2012: Advanced Cell Technology Receives Data And Safety Monitoring Board Approval To Increase RPE Dosage For Stargardt’s Disease Patients In US Trial 64

Apr 23, 2012: Cell Cure Neurosciences Provides Update On OpRegen Product Development 65

Apr 20, 2012: Advanced Cell Technology Doses Third Patient In US Phase I/II Study Of Retinal Pigment Epithelial Cells To Treat Dry AMD 66

Apr 16, 2012: Advanced Cell Technology Doses Second Patient In US Phase I/II Study Of Retinal Pigment Epithelial Cells To Treat Dry AMD 67

Apr 11, 2012: MacuCLEAR To Begin Phase III Study Of MC-1101 For Early-Stage Age-Related Macular Degeneration 67

Apr 04, 2012: ACT Announces Approval Of Bascom Palmer Eye Institute As Additional Site For Stem Cell Clinical Trial For Dry Age-Related Macular Degeneration 68

Appendix 69

Methodology 69

Coverage 69

Secondary Research 69

Primary Research 69

Expert Panel Validation 69

Contact Us 70

Disclaimer 70





List of Tables

Number of Products Under Development for Dry (Atrophic) Macular Degeneration, H1 2012 8

Products under Development for Dry (Atrophic) Macular Degeneration — Comparative Analysis, H1 2012 9

Number of Products under Development by Companies, H1 2012 11

Comparative Analysis by Late Stage Development, H1 2012 12

Comparative Analysis by Mid Clinical Stage Development, H1 2012 13

Comparative Analysis by Early Clinical Stage Development, H1 2012 14

Comparative Analysis by Pre-Clinical Stage Development, H1 2012 15

Products under Development by Companies, H1 2012 16

Alcon, Inc., H1 2012 17

Genentech, Inc., H1 2012 18

Pfizer Inc., H1 2012 19

Ophthotech Corp., H1 2012 20

Sirion Therapeutics, Inc., H1 2012 21

Sucampo Pharmaceuticals, Inc., H1 2012 22

Acucela Inc., H1 2012 23

Aciont Inc., H1 2012 24

Neurotech Pharmaceuticals, Inc., H1 2012 25

Inotek Pharmaceuticals Corporation, H1 2012 26

Alimera Sciences, Inc., H1 2012 27

MacuCLEAR, Inc., H1 2012 28

Assessment by Monotherapy Products, H1 2012 29

Assessment by Stage and Route of Administration, H1 2012 31

Assessment by Stage and Molecule Type, H1 2012 33

Dry (Atrophic) Macular Degeneration Therapeutics — Drug Profile Updates 54

Dry (Atrophic) Macular Degeneration Therapeutics — Dormant Products 61





List of Figures

Number of Products under Development for Dry (Atrophic) Macular Degeneration, H1 2012 8

Products under Development for Dry (Atrophic) Macular Degeneration — Comparative Analysis, H1 2012 9

Products under Development by Companies, H1 2012 10

Late Stage Products, H1 2012 12

Mid Clinical Stage Products, H1 2012 13

Early Clinical Stage Products, H1 2012 14

Pre-Clinical Stage Products, H1 2012 15

Assessment by Monotherapy Products, H1 2012 29

Assessment by Route of Administration, H1 2012 30

Assessment by Stage and Route of Administration, H1 2012 31

Assessment by Molecule Type, H1 2012 32

Assessment by Stage and Molecule Type, H1 2012 33

• Eye Care in Canada
• Eye Care in Denmark
• Eye Care in Hong Kong, China
• Eye Care in Norway
• Age Related Macular Degeneration – Pipeline Review, H1 2013
• Choroidal Neovascularization – Pipeline Review, H1 2013
• Eye Care in Algeria
• Eye Care in Azerbaijan
• Eye Care in Chile
• Eye Care in China
• Eye Care in Finland
• Eye Care in Greece
• Eye Care in Kazakhstan
• Eye Care in Latvia
• Eye Care in Lithuania
• Eye Care in Poland
• Eye Care in Sweden
• Eye Care in the US
• Eye Care in Uzbekistan
• Global Eye Care Surgical Market  2012-2016